Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)

Sponsor
Asan Medical Center (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04988984
Collaborator
(none)
400
1
37.4
10.7

Study Details

Study Description

Brief Summary

It is intended for patients who have been admitted to the outpatient or emergency room or are hospitalized For patients who diagnose pulmonary tuberculosis or extrapulmonary tuberculosis using Xpert TB/RIF, additionally, diagnose pulmonary tuberculosis or extrapulmonary tuberculosis using a new diagnostic method, and check the test results. Check whether the tuberculosis bacteria were actually cultured in the sample in the future, and compare the sensitivity and specificity in each test.

Validation in animal model In an animal model (rat) with chronic obstructive pulmonary disease that shows similar characteristics to tuberculosis destructive lung, It will be investigated whether the HI method can be validated by separating and concentrating microbiome for various pathogens including Mycobacterium tuberculosis using HI method. Confirm.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Usefulness of Pulmonary Tuberculosis Diagnosis A comparison of the new diagnostic method with the Xpert TB/RIF test, which is widely used in clinical practice, that can quickly diagnose pulmonary tuberculosis within 1-2 days. ; Considering the sensitivity of the Xpert TB/RIF test as 70% and the sensitivity of the new diagnostic method as 90%, the number of patients with pulmonary tuberculosis required to confirm that the new diagnostic method is useful is estimated as 90 (study power 90%, alpha error = 0.05). And, if 200 patients with suspected pulmonary tuberculosis are registered, it is possible to verify the clinical usefulness compared to Xpert TB/RIF even in 60 AFB smear negative patients. In addition, for the same reason, if 150 additional patients who underwent bronchoscopy were enrolled, it would be possible to compare the diagnosis rate and utility of sputum and bronchoscopy fluid. Waiting for the tuberculosis bacteria culture test for 6 weeks and using the final culture-positive patient as a gold standard for tuberculosis diagnosis -Usefulness of extrapulmonary tuberculosis diagnosis

    Millet tuberculosis is disseminated tuberculosis through blood, and there are numerous millet-like lesions in the lungs, but in fact, the positive rate of AFB smear is low due to paucibacillary TB. It is planned to prove the usefulness of the new test method in 35 people with millet tuberculosis.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    400 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Development of Device Kit for Rapid and Sensitive Diagnostic Method for the Tuberculosis; Using Amine Groups Called HI(Homobifunctional Imidoesters),Negative Charge of the Pathogen and Formed Electrical Bonding to Isolate and Concentrate the Pathogen
    Actual Study Start Date :
    Nov 17, 2020
    Actual Primary Completion Date :
    Nov 17, 2020
    Anticipated Study Completion Date :
    Dec 31, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    Suspected TB

    Patient suspected of TB undergoing diagnostic testing.

    Outcome Measures

    Primary Outcome Measures

    1. Sensitivity and specificity when using Xpert TB/RIF tests with [From date of experiment until the date of first documented progression assessed upto 100 months]

      Comparison of sensitivity and specificity of existing Xpert TB/RIF tests and new diagnostic methods using Homobifunctional Imidoesters (HI) compounds in diagnosing suspected cases of pulmonary tuberculosis and pulmonary tuberculosis And the sensitivity and specificity of these two test results are evaluated by waiting for the tuberculosis bacillus culture test for 6 weeks and using the final culture-positive patient as a gold standard for tuberculosis diagnosis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 100 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Pulmonary TB

    • Extrapulmonary TB

    Exclusion Criteria:
    • under 19

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Asan Medical Center, University of Ulsan College of Medicine Seoul Songpa Korea, Republic of 05505

    Sponsors and Collaborators

    • Asan Medical Center

    Investigators

    • Principal Investigator: Seiwon Lee, Asan Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Sei Won Lee, Associate Professor, Asan Medical Center
    ClinicalTrials.gov Identifier:
    NCT04988984
    Other Study ID Numbers:
    • 2020-1745
    First Posted:
    Aug 4, 2021
    Last Update Posted:
    Aug 4, 2021
    Last Verified:
    Jul 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Sei Won Lee, Associate Professor, Asan Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 4, 2021